{"id":"https://openalex.org/W2018609823","doi":"https://doi.org/10.1016/j.jval.2012.03.777","title":"PND18 Cost- Effectiveness of Fingolimod on Patients With Multiple Sclerosis at the Public Mexican Health Care System","display_name":"PND18 Cost- Effectiveness of Fingolimod on Patients With Multiple Sclerosis at the Public Mexican Health Care System","publication_year":2012,"publication_date":"2012-05-23","ids":{"openalex":"https://openalex.org/W2018609823","doi":"https://doi.org/10.1016/j.jval.2012.03.777","mag":"2018609823"},"language":"en","primary_location":{"id":"doi:10.1016/j.jval.2012.03.777","doi":"https://doi.org/10.1016/j.jval.2012.03.777","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2012.03.777","pdf_url":"http://www.valueinhealthjournal.com/article/S109830151200842X/pdf","source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"http://www.valueinhealthjournal.com/article/S109830151200842X/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5024441531","display_name":"IF Soria-Cedillo","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"I.F. Soria-Cedillo","raw_affiliation_strings":["IS&VB Consultants, Tecamac, Mexico"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"IS&VB Consultants, Tecamac, Mexico","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072184994","display_name":"VI Baca-Muro","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"V. Baca-Muro","raw_affiliation_strings":["IS&VB Consultants, Tecamac, Mexico"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"IS&VB Consultants, Tecamac, Mexico","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028296167","display_name":"L. Garc\u00eda-Conde","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210125565","display_name":"Novartis (Mexico)","ror":"https://ror.org/02dbytc62","country_code":"MX","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210125565"]}],"countries":["MX"],"is_corresponding":false,"raw_author_name":"L. Garc\u00eda-Conde","raw_affiliation_strings":["Novartis Pharmaceuticals Corporation, Mexico City, Mexico"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, Mexico City, Mexico","institution_ids":["https://openalex.org/I4210125565"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5038720341","display_name":"Edith Arely Lemus-Carmona","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210125565","display_name":"Novartis (Mexico)","ror":"https://ror.org/02dbytc62","country_code":"MX","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210125565"]}],"countries":["MX"],"is_corresponding":false,"raw_author_name":"E. Lemus-Carmona","raw_affiliation_strings":["Novartis Pharmaceuticals Corporation, Mexico City, Mexico"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, Mexico City, Mexico","institution_ids":["https://openalex.org/I4210125565"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4000,"currency":"USD","value_usd":4000},"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"15","issue":"4","first_page":"A144","last_page":"A144"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9398999810218811,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9398999810218811,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.05860000103712082,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fingolimod","display_name":"fingolimod","score":0.9089999794960022},{"id":"https://openalex.org/keywords/relapsing-remitting-multiple-sclerosis","display_name":"relapsing-remitting multiple sclerosis","score":0.9990000128746033},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9789999723434448},{"id":"https://openalex.org/keywords/glatiramer-acetate","display_name":"glatiramer acetate","score":0.9509999752044678},{"id":"https://openalex.org/keywords/interferon-beta","display_name":"interferon-beta","score":0.9629999995231628},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.7139999866485596},{"id":"https://openalex.org/keywords/relapse-rate","display_name":"relapse rate","score":0.6190000176429749},{"id":"https://openalex.org/keywords/expanded-disability-status-scale","display_name":"Expanded Disability Status Scale","score":0.8330000042915344},{"id":"https://openalex.org/keywords/treatment-costs","display_name":"treatment costs","score":0.3659999966621399},{"id":"https://openalex.org/keywords/drug-costs","display_name":"drug costs","score":0.36000001430511475},{"id":"https://openalex.org/keywords/health-technology-assessment","display_name":"health technology assessment","score":0.4819999933242798},{"id":"https://openalex.org/keywords/markov-model","display_name":"Markov model","score":0.5410000085830688},{"id":"https://openalex.org/keywords/mexico-city","display_name":"Mexico City","score":0.31200000643730164},{"id":"https://openalex.org/keywords/freedom","display_name":"freedom","score":0.5389999747276306},{"id":"https://openalex.org/keywords/transforms","display_name":"transforms","score":0.9950000047683716}],"concepts":[{"id":"https://openalex.org/C2776036978","wikidata":"https://www.wikidata.org/wiki/Q425137","display_name":"Fingolimod","level":3,"score":0.9706481695175171},{"id":"https://openalex.org/C2778577042","wikidata":"https://www.wikidata.org/wiki/Q418274","display_name":"Glatiramer acetate","level":3,"score":0.8960543870925903},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7071253061294556},{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.4538328945636749},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.43916499614715576},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.10858854651451111},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.08384272456169128}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.jval.2012.03.777","doi":"https://doi.org/10.1016/j.jval.2012.03.777","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2012.03.777","pdf_url":"http://www.valueinhealthjournal.com/article/S109830151200842X/pdf","source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.jval.2012.03.777","doi":"https://doi.org/10.1016/j.jval.2012.03.777","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2012.03.777","pdf_url":"http://www.valueinhealthjournal.com/article/S109830151200842X/pdf","source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2018609823.pdf","grobid_xml":"https://content.openalex.org/works/W2018609823.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3026620581","https://openalex.org/W2414286345","https://openalex.org/W2005611486","https://openalex.org/W2334416729","https://openalex.org/W2766137905","https://openalex.org/W2319422612","https://openalex.org/W2054574473","https://openalex.org/W2748028077","https://openalex.org/W2536731607","https://openalex.org/W1963948683"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2016-06-24T00:00:00"}